FIND CLINICAL TRIALS

Am I Eligible?
Image, older male patient sitting outdoors

Investigating a potential treatment for people with newly diagnosed cholangiocarcinoma

Help researchers investigate a potential new treatment in a clinical study.

Am I Eligible?

About FIGHT-302

WHAT IS FIGHT-302?

Image, male scientist using a computer in a laboratory

FIGHT-302 is a clinical study investigating the safety and efficacy of a potential treatment for patients newly diagnosed with cholangiocarcinoma with FGFR2 rearrangements.

WHO IS THIS STUDY FOR?

Image, female doctor speaking with a patient

The study is recruiting people over 18 years old with cholangiocarcinoma with FGFR2 rearrangements who have not previously received treatments and in which the cancer has either spread or for those in which surgery is not an option.

About Cholangiocarcinoma

WHAT IS CHOLANGIOCARCINOMA?

Image, anatomy of the bile duct tube connecting to the liver, gallbladder and small intestine with labels to show locations for intrahepatic cholangiocarcinoma

Cholangiocarcinoma (CCA), more commonly known as bile duct cancer, is a rare type of cancer that impacts around 8,000 people in the United States each year.1

The bile duct is a thin tube that connects the liver to the gallbladder and small intestine. The duct carries the digestive fluid known as bile that helps the body break down fats.2

Bile duct cancer can occur inside or outside the liver. When bile duct cancer occurs inside the liver, it is called intrahepatic cholangiocarcinoma.2

Find out more about cholangiocarcinoma
Image, anatomy of the bile duct tube connecting to the liver, gallbladder and small intestine with labels to show locations for intrahepatic cholangiocarcinoma
Image, male scientist analyzing tube in a laboratory

DIAGNOSING CHOLANGIOCARCINOMA

Image, male scientist analyzing tube in a laboratory

There are tests and procedures available to diagnose bile duct cancer. Blood chemistry tests, for example, can help to identify bile duct irregularities by detecting high levels of certain liver enzymes.3

Other procedures that can help diagnose bile duct cancer and bile duct irregularities include abdominal ultrasounds, magnetic resonance imaging (MRI), computed tomography (CT) scans, endoscopy, as well as biopsy. 3

DETECTING FGFR2 FUSIONS OR REARRANGEMENTS WITH MOLECULAR PROFILING

Image, test tubes in a laboratory

FGFR2 fusions or rearrangements are molecular defects (mutations) that can occur in the FGFR2 gene and can lead to cancer.4

The fusion or rearrangement of the FGFR2 gene is often detectable early in disease progression through molecular profiling.5

Molecular profiling, a detailed study of tumor samples to see what may be driving the cancer, can help identify genetic defects typically found in different types of cancer.

Molecular profiling can also help doctors better understand each patient’s tumor and, therefore, make optimum treatment decisions. If you have bile duct cancer, ask your doctor about molecular profiling for FGFR2 fusions or rearrangements.

Learn about
"why mutations matter" Find additional resources at the
Cholangiocarcinoma Foundation®
Image, test tubes in a laboratory

References:

  1. American Cancer Society. Key statistics for bile duct cancer. https://www.cancer.org/cancer/bile-duct-cancer/about/key-statistics.html. Accessed February 2020.
  2. American Cancer Society. What is bile duct cancer? https://www.cancer.org/cancer/bile-duct-cancer/about/what-is-bile-duct-cancer.html. Accessed February 2020.
  3. American Cancer Society. Tests for Bile Duct Cancer. https://www.cancer.org/cancer/bile-duct-cancer/detection-diagnosis-staging/how-diagnosed.html. Accessed February 2020.
  4. Sia D, et al. Nat Commun. 2015;6:6087.
  5. Jain A, et al. JCO Precis Oncol. 2018:1-12. doi: 10.1200/PO.17.00080.

Clinical Study Locations

FIND A CLINICAL STUDY LOCATION NEAR YOU

Which state is that? Hover over it to find out.
Search

See here for the complete list of locations for the FIGHT-302 clinical study.

Incyte Medical Information Center

1-855-463-3463

CALL

Eligibility & Enrollment Information

FIND OUT IF THE FIGHT-302 STUDY COULD BE RIGHT FOR YOU

Interested in participating in the FIGHT-302 study?

Take this Eligibility Quiz to see if you may be eligible to enroll.

Talk with your doctor if you have questions about your diagnosis. If you are filling this out on behalf of a patient, please answer based on the patient’s information.

Are you 18 years or older?


Next >

Have you been diagnosed with metastatic or surgically unresectable cholangiocarcinoma?


Next >

Have you previously been treated for cholangiocarcinoma?


Next >

Do you have FGFR2 fusions or rearrangements?


Next >

THANK YOU!

You may be eligible to participate in the FIGHT-302 clinical study. Use the map above to find a study location in your area and connect with a study coordinator to get further information.

THANK YOU!

Based on your response, at this time, it looks like you have not met the eligibility requirements to enroll in the FIGHT-302 clinical study.

Please use the Doctor Discussion Guide below for tips on how to talk with your doctor about your diagnosis, treatment options, and clinical studies that may be right for you.

Doctor Discussion Guide

We’re recruiting patients who meet the following criteria for the FIGHT-302 clinical study:

CONDITION


Unresectable Cholangiocarcinoma
Metastatic Cholangiocarcinoma

GENDER


Image, gender criteria labeled in blue box with male and female icons

AGE


18+

Additional Resources

DOCTOR DISCUSSION GUIDE


Downloadable PDF

FACT SHEET


Downloadable PDF
: A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
: 3
: Interventional
: December 13, 2018
: October 31, 2023
: NCT03656536
: United States, Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Netherlands, Norway, Spain, Sweden, Switzerland, United Kingdom